Summary
On October 27, 2026, Anthropic officially published early results of Claude in drug development: key numbers from six partners (BigHat, BMS, Divergence Labs, Enveda, Generate Biomedicines, The Column Group) and its own Mithril pipeline, covering molecule counts, hit rates and time saved.
Background and Data Scope
- Event: Anthropic's official research post (2026-10-27) disclosed early progress of Claude in drug development, with six partners: BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group.
- Sources: All metrics are as disclosed in Anthropic's official research post.
- Scope: Molecule design counts, experimental cycles and hit rates follow the disclosed figures of each partner program.
Core Data Table
| model | development stage | key metric | result data |
|---|---|---|---|
| Generate Biomedicines | CAR-T solid-tumor engineering | gene segment length, receptor yield | newly designed gene segments about 70% shorter than the standard version; immune cell receptor yield about 10x |
| Divergence Labs | food-allergy antibody design | antibody designs, hits | about 35,000 antibody designs generated autonomously in about a month; 3 IgE-binding and 20 IgE-stripping hits, of which 3 outperform standard drugs |
| BigHat Biosciences | lead optimization | variants, binding affinity, stability | about 1,010 variants tested in about 10 weeks; best binding affinity improved 10x or more; solubility temperature ceiling of the oncology lead raised 18°C; aggregation slowed 100x or more |
| Enveda | manufacturing & regulatory document review | issue detection, review time | reviewed 1,061 pages of manufacturing documents; Claude caught all 11 issues found manually and flagged 7 additional omissions; human review time cut 89% (25+ hours to under 3); a first regulatory draft completed in 4 hours (about 3 months manually) |
| The Column Group (Pleiades) | startup incubation | target-disease pairs evaluated | first Claude skill evaluated across 45 target-disease pairs |
| Bristol Myers Squibb | drug development partnership | partnership expansion | collaboration to expand in 2027 |
| Mithril Medicine (in-house pipeline) | solo-founder pipeline | lab partnerships, cycle time | 11 external labs engaged; idea to positive mouse results in under 18 months; first-in-human clinical use as early as late 2028 expected |
Supplementary Note
- Mithril Medicine is a solo-founder company and has been acquired by Anthropic.